MET Receptors
The MET receptor, also known as hepatocyte growth factor receptor (HGFR), is a proto-oncogenic receptor tyrosine kinase. The endogenous ligand for MET is hepatocyte growth factor/scatter factor (HGF), a disulfide-linked heterodimeric molecule.
MET Receptor Inhibitors |
|
|---|---|
| Cat. No. | Product Name / Activity |
| 4368 | Crizotinib |
| Potent c-MET/ALK inhibitor | |
| 1683 | K 252a |
| Receptor tyrosine kinase inhibitor, inhibits MET | |
| 4239 | PF 04217903 mesylate |
| Highly selective MET inhibitor | |
| 2693 | PHA 665752 |
| Potent and selective MET inhibitor | |
| 5356 | SGX 523 |
| Selective and potent c-MET kinase inhibitor | |
| 3037 | SU 5416 |
| MET inhibitor. Also inhibits KIT, RET, VEGFR and FLT3 | |
| 5422 | XL 184 |
| Potent c-MET inhibitor; also inhibits other RTKs | |
Degraders |
|
| Cat. No. | Product Name / Activity |
| 7266 | SJF 8240 |
| c-MET Degrader; also degrades exon-14-deleted c-MET | |
The MET receptor, also known as hepatocyte growth factor receptor (HGFR), is a proto-oncogenic receptor tyrosine kinase. The endogenous ligand for the MET receptor is hepatocyte growth factor/scatter factor (HGF), a disulfide-linked heterodimeric molecule produced predominantly by mesenchymal cells.
In the adult, MET receptor expression is limited to stem and progenitor cells and is necessary for wound healing and hepatocyte regeneration. In the embryo, MET receptors are expressed on cells of epithelial origin. They are essential for invasive growth and mediate epithelial-mesenchymal transition (EMT).
Aberrant activation of the HGF/MET pathway leads to a variety of cancers. MET receptor mutations are associated with poor prognosis as they can trigger tumor growth, angiogenesis and metastasis.